Skip to main content
Premium Trial:

Request an Annual Quote

MolecularMD, Genoptix Ink Marketing Agreement for CDx to Novartis CML Drug

NEW YORK (GenomeWeb) – Diagnostics firm MolecularMD has signed an exclusive agreement with clinical oncology laboratory Genoptix to market, distribute, and perform diagnostic testing services for the MRDx BCR-ABL companion diagnostic test.

Under the terms of the agreement, Genoptix will be the exclusive provider in the US of MRDx testing services and kits. Financial terms of the deal were not disclosed.

The MolecularMD test — which was authorized by the US Food and Drug Administration about six months ago — is a real-time PCR-based assay intended to identify chronic myeloid leukemia patients taking the Novartis drug Tasigna (nilotinib) who are Philadelphia chromosome positive and are candidates for stopping treatment and starting treatment-free remission (TFR) monitoring. Specifically, these patients no longer take daily oral therapy with Tasigna but continue to have frequent monitoring of their molecular response using the MRDx BCR-ABL test.

"The addition of MolecularMD's MRDx BCR-ABL Test as a companion diagnostic with Tasigna enhances Genoptix's portfolio of minimal residual disease clinical monitoring tools and strengthens our position as a leader in hematology oncology," Genoptix President and CEO Joseph Limber said in a statement.

"Following MolecularMD's FDA authorization of the MRDx Test for TFR, the commercial partnership with Genoptix will provide broad market access and ensure that CML patients and their healthcare providers receive timely and accurate test results in the management of therapy discontinuation," added MolecularMD CEO Dan Snyder.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more